Oral antiplatelet therapy for acute ischaemic stroke

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Sandercock, Peter A G ^a   Counsell, Carl ^b   Tseng, Mei Chiun ^c   Cecconi, Emanuela ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; ISBOGREL; PAMICOGREL; PLACEBO; SARPOGRELATE; SATIGREL; STREPTOKINASE; TICLOPIDINE;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMBINATION DRUG THERAPY; CONVALESCENCE; DEATH; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; LUNG EMBOLISM; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CEREBROVASCULAR ACCIDENT; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; TIME TO TREATMENT;

ASPIRIN; BRAIN ISCHEMIA; DIPYRIDAMOLE; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; STROKE; TICLOPIDINE; TIME-TO-TREATMENT;

EID: 84904890493     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000029.pub3     Document Type: Review

References (105)

1. CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20, 000 patients with acute ischaemic stroke. Lancet 1997;349:1641-9.
2. Ciuffetti G, Aisa G, Mercuri M, Lombardini R, Paltriccia R, Neri C, et al.Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology 1990;41:505-11.
3. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
4. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-14.
5. Pince J. Thromboses veineuses des membres inferieures et embolies pulmonaires au cours des accidents vasculaires cerebraux. A propos d'un essai comparatif de traitment preventif. (These pour le doctorat d'etat en medicine). Toulouse: Universite Paul Sabatier, 1981.
6. Rödén-Jüllig Å, Britton M, Malmkvist K, Leijd B. Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine 2003;254:584-90.
7. Turpie AGG, Dobkin B, McKenna R. A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188) 1983.
8. Utsumi H. Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128) 1984.
9. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose escalation study. Stroke 2000;31:601-9.
10. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke. Results of a randomized phase 2 trial. Stroke 2005;36:880-90.
11. Adams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, et al.Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008;39:87-99.
12. Adams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, et al.Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008;39:87-99.
13. Adams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, et al.Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008;39:87-99.
14. Aoki T. Prolonged administration of ticlopidine to cerebral infarction. Unpublished. [: Cochrane Stroke Group Trials Register ID 3461]
15. Harrington RA, Armstrong PW, et al.for the Anti-PLAtelet Useful Dose (APLAUD) Study Investigators. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation 2000;102:728-35. [MEDLINE: 20402310]
16. Apollonia A, Castignani P, Magrini L, Angeletti R. Ticlopidine-pentoxiphylline combination in the treatment of atherosclerosis and the prevention of cerebrovascular accidents. Journal of International Medical Research 1989;17:28-35.
17. Zinkstok SM, Roos YB, ARTIS investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 2012;380(9843):731-7. [DOI: 10.1016/S0140-6736(12)60949-0]
18. Balkuv-Ulutin S, Hacihanifioglu M, Ulutin UN. Clinical and laboratory results obtained with defibrotide in the case of acute stroke. Thrombosis and Haemostasis 1989;62:585.
19. Topol EJ, Easton JD, Amarenco P, Califf R, Harrington R, Graffagnino C, et al.Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. American Heart Journal 2000;139:927-33. [MEDLINE: 20287265]
20. Chen J, Ye M, Wei J. Hemorrheological study on the effect of acupuncture in treating cerebral infarction. Journal of Traditional Chinese Medicine 1988;8:167-72. [: Cochrane Stroke Group Trials Register id 4731]
21. Cheung RTF, Ho DSW. Fatal hemorrhagic transformation of acute cerebral infarction after the use of abciximab. Stroke 2000;31:2518-9.
22. Pancioli A, for the CLEAR Trial Investigators. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke (the CLEAR stroke trial): blinded results from tier I and II. Proceedings of the International Stroke Conference; 2006 February 16-18; Kissimmee (FL), USA. 2006:(Abstract CTP17).
23. Pancioli AM, Broderick JP, the CLEAR Stroke Trial Investigators. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke (The CLEAR Stroke Trial). Proceedings of the 29th International Stroke Conference; 2004 February 5-7; San Diego (CA), USA. 2004:(Abstract CTP16).
24. D'Andrea G, Cananzi AR, Alecci M, Perini F, Zamberlan F, Milone FF. Study of effect of picotamide, ASA, and picotamide plus ASA on platelet aggregation in ischemic stroke. Canadian Journal of Neurological Sciences 1993;20 Suppl 4:s23.
25. D'Andrea G, Perini F, Hasselmark L, Alecci M, Cananzi AR. Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. Functional Neurology 1995;10:91-8.
26. Fan DL. Clinical research of ligustrazine for acute cerebral infarction. Chinese Journal of Hemorheology 2003;13:250.
27. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM, et al.Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurology 2007;6:961-9.
28. Gao B, Hu ZX, Li CM. The effect of ligustrazine, aspirin and betahistine on the platelet aggregation of ischemic stroke patients. Chinese Journal of Neurology and Psychiatry 1989;22:148-51. [: Cn-00280553]
29. Garcia Tigera J, Martinez Dreke R. Levamisol, a new treatment for cerebral infarction [Abstract]. Journal of Neurology 1994;241 Suppl 1:S162.
30. Hakim AM, Pokrupa RP, Wolfe LS. Preliminary report on the effectiveness of prostacyclin in stroke. Canadian Journal of Neurological Sciences 1984;11:409.
31. Iida N. Clinical experience with ticlopidine in patients with cerebral infarction. Unpublished data 1984.
32. Uchiyama S, Ikeda Y, Urano Y, Horie Y, Yamaguchi T. The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. Cerebrovascular Diseases 2011;31:601-13. [DOI: 10.1159/000327035]
33. Joseph R, Welch KM, D'Andrea G. Effect of therapy on platelet activation factor induced aggregation in acute stroke. Stroke 1989;20:609-11.
34. Junghans U, Seitz R, Wittsack H, Fink GR, Freund H, Siebler M. Ischaemic brain tissue salvaged by infarction by the GP IIb/IIa platelet antagonist tirofiban. Neurology 2002;58:474-6.
35. Kamath S, Lip GY. YM-337 Yamanouchi. Current Opinion in Investigational Drugs 2001;2:1093-6.
36. Kaye J. A trial to evaluate the relative roles of dipyridamole and aspirin in the prevention of deep vein thrombosis in stroke patients. Brackness (UK): Boehringer Ingelheim (Internal report trial no. CT 330/189) 1989.
37. Lecrubier C, Conard J, Samama M, Bousser M-G. Randomised trial of a new platelet anti-aggregant agent: ticlopidine. Therapie 1977;32:189-94.
38. Li SH, Li DY, Wang YJ, Guo H, Cheng CY, Zhao J. Study of optimal aspirin loading and maintaining dosage for cerebral infarction at acute stage. Chinese Journal of Neurology 1999;32:302. [: Cn-00282304]
39. Li GY, Lin YX, Zhou Y, Song LF, Li BC. Effect of ozagrel sodium in ameliorating the motor function of patients with acute lacunar infarct of dyskinesias: A randomized, double-blind, placebo-controlled trial. Chinese Journal of Clinical Rehabilitation 2005;9:4-5.
40. Liu X, Li X, Miao L, Wang Q, Bao L. Therapeutic observation and biochemical study of calcium antagonist and anti-thromboxane A2 activity in acute ischaemic stroke. Journal of Apoplexy and Nervous Diseases 1994;11:72-4.
41. Matsumoto Y. Comparison of the effects between ozagrel Na combined with cilostazol and ozagrel Na alone for acute phase ischemic stroke in the territory of perforating arteries of the MCA: a randomized open trial. UMIN Clinical Trials Registry. center.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi (accessed 8 August 2007).
42. Monreal M, Lafoz E, Foz M, Monasterio J. Aspirin and the kidney in patients with cerebral ischemia. Thrombosis and Haemostasis 1987;58:548.
43. Ohtomo E, Kutsuzawa T, Kogure K, Hirai S, Goto F, Terashi Am Tazaki Y, et al.Clinical usefulness of OKY-046 on the acute stage of cerebral thrombosis - double blind trial in comparison with placebo. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicine) 1991;7:353-88.
44. Siebler M, Hennerici MG, Schneider D, von Reutern GM, Seitz RJ, Röther J, et al.Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial. Stroke 2011;42:2388-92. [DOI: 10.1161/STROKEAHA.110.599662]
45. Seitz RJ, Meisel S, Moll M, Wittsack H-J, Junghans U, Siebler M. The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions. Neurology 2004;62:2110-2.
46. Siebler M. Cerebral microembolism is blocked by tirofiban, a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist. Circulation 2003;107:2717-21.
47. Marini C, Rothwell P, Di Orio F, Maragliano E. Efficacy and safety of ticlopidine and aspirin versus aspirin alone in the prevention of vascular events after cerebral ischaemia. Unpublished 2000.
48. Bath P. Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke (TARDIS) http://www.controlled-trials.com/ISRCTN47823388. http://www.tardistrial.org/.
49. Bo W, Ming L, Song T. A randomized controlled trial of ligustrazine for acute ischemic stroke. Journal of the Neurological Sciences 2005;238 Suppl 1:S415.
50. Yan FL, Xu YM, Ma JM. Clinical investigation of ticlopidine hydrochloride in the treatment of cerebral infarction. Chinese Journal of Practical Internal Medicine 1998;18:657.
51. Zhang D, Zhu S, Cui G, Li Y, Zhang H, Xia Z, Ren W. Clinical study of low-molecular-weight heparin calcium and aspirin therapy on acute cerebral infarction. Chinese Pharmaceutical Journal 2005;40:634-6.
52. Fujimoto S, Jinnouchi J, Inoue T, Suzuki S, Sadoshima S. Effect of combined antithrombotic treatment with cilostazol for progressive stroke. International Journal of Stroke 2010;5 Suppl 2:87-8.
53. Wang C, Wang Y, Gao Y. Randomized placebo-controlled trial of early aspirin used in 180 patients with acute ischaemic stroke in the elderly people. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease 2000;8:19-21.
54. Suzuki N. Cilostazol in Acute Ischemic Stroke Trial. UMIN Clinical Trials Registry (UMIN-CTR). (http://www.umin.ac.jp/ctr/) 2006.
55. Tominaga T. A randomized clinical trial of an antiplatelet agent in the treatment of acute stroke: cilostazol in the prevention of acute progressing stroke (CAPS) study. UMIN Clinical Trials Registry (UMIN-CTR) (http://www.umin.ac.jp/ctr/) 2009.
56. Adams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, et al.Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008;39:87-99.
57. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013;127::e6-e245. [DOI: 10.1161/CIR.0b013e31828124ad]
58. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
59. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994;308:235-46.
60. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 2002;324:71-86.
61. Antithrombotic Trialists Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
62. Bamford J, Sandercock P, Warlow C, Slattery J. Inter-observer agreement for the assessment of handicap in stroke patients. Stroke 1989;20:8.
63. Bath PMW. Prostacyclin and analogues for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD000177.pub2]
64. Bath PMW, Bath-Hextall FJ. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD000162.pub2]
65. Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, et al.Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Cerebrovascular Diseases 2011;32:65-71. [DOI: 10.1159/000327036]
66. Candelise L, Pinardi G, Aritzu E, Musicco M. Telephone interview for stroke outcome assessment. Cerebrovascular Diseases 1994;4:341-3.
67. Chairangsarit P, Sithinamsuwan P, Niyasom S, Udommongkol C, Nidhinandana S, Suwantamee J. Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. Journal of the Medical Association of Thailand 2005;88:S148-S154.
68. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine 2013;369:11-9. [DOI: 10.1056/NEJMoa1215340]
69. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, et al.Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40, 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST Collaborative Groups. Stroke 2000;31:1240-9.
70. Ciccone A, Abraha I, Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD005208.pub2]
71. Collins R, MacMahon S, Flather M, Baigent C, Remviq L, Mortensen S, et al.Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic review of randomised trials. BMJ 1996;313:652-9.
72. Canadian Stroke Network and Heart and Stroke Foundation of Canada. Canadian Best Practice Recommendations for Stroke Care: Update 2010. http://www.canadianstrokenetwork.ca/ December 2010.
73. Dalen JE. Aspirin to prevent heart attack and stroke: what's the right dose?. American Journal of Medicine 2006;119:198-202.
74. Davenport R, Dennis M, Wellwood I, Warlow C. Complications after acute stroke. Stroke 1996;27:415-20.
75. Dennis M, Wellwood I, Warlow C. Are simple questions a valid measure of outcome after stroke?. Cerebrovascular Diseases 1997;7:22-7.
76. Dengler R, Diener HC, Schwartz A, Grond M, Schumacher H, Machnig T, EARLY Investigators. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurology 2010;9:159-66. [DOI: 10.1016/S1474-4422(09)70361-8]
77. The European Stroke Organisation Executive Committee and the ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovascular Diseases 2008;25::457-507. [DOI: 10.1159/000131083]
78. Hankey GJ, Hacke W, Easton JD, Johnston SC, Mas JL, Brennan DM, CHARISMA Trial Investigators. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. International Journal of Stroke 2010;41:1679-83. [DOI: 10.1161/STROKEAHA.110.586727]
79. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
80. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data and outcome in 984 randomised patients in the pilot study. Journal of Neurology, Neurosurgery, and Psychiatry 1996;60:371-6.
81. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947. [DOI: 10.1161/STR.0b013e318284056a]
82. Kamal AK, Siddiqi SA, Naqvi I, Khan M, Majeed F, Ahmed B. Multiple versus one or more antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD009716]
83. Keir S, Wardlaw J, Sandercock PAG, Chen Z. Antithrombotic therapy in patients with any form of intracranial haemorrhage: a systematic review of the available controlled studies. Cerebrovascular Diseases 2002;14(3-4):197-206.
84. Dick E. Stroke: A focus of opportunity. St. Louis, USA: MedStrategy, 1995.
85. Murray C, Lopez A. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76.
86. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al.Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-223.
87. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. New England Journal of Medicine 1995;333:1581-7.
88. Odgaard-Jensen J, Vist GE, Timmer A, Kunz R, Akl EA, Schünemann H, et al.Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.MR000012.pub3]
89. Patrono C. Aspirin as an antiplatelet drug. New England Journal of Medicine 1994;330:1287-94.
90. Patrono C, Coller B, Dalen JE, Fuster V, Gent M, Harker LA, et al.Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998;114:470S-88S.
91. POINT Investigators. Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial. http://www.pointtrial.org.
92. Royal College of Physicians. National Clinical Guidelines for Stroke, Fourth edition 2012. http://www.rcplondon.ac.uk/resources/stroke-guidelines September 2012.
93. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
94. Ricci S, Celani MG, Cantisani TA, Righetti E. Piracetam for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD000419.pub3]
95. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurology 2007;6:182-7.
96. Suri MF, Hussein HM, Abdelmoula MM, Divani AA, Qureshi AI. Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. Medical Science Monitor 2008;14:I39-44.
97. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database of Systematic Reviews 2013, Issue 9. [DOI: 10.1002/14651858.CD000197.pub3]
98. Tsai CF, Thomas B, Sudlow CLM. Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology 2013;81(3):264-72.
99. van Gijn J. Aspirin: dose and indications in modern stroke prevention. Neurologic Clinics 1992;10:193-209.
100. van Kooten F, Ciabattone G, Patrono C, Schmitz PI, van Gijn J, Koudstaal PJ. Evidence for episodic platelet activation in acute ischaemic stroke. Stroke 1994;25:278-81.
101. van Kooten F, Ciabattoni G, Patrono C, Dippel DW, Koudstaal PJ. Platelet activation and lipid peroxidation in patients with acute ischaemic stroke. Stroke 1997;28:1557-63.
102. Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD000213.pub2]
103. Warlow C. Stroke, transient ischaemic attacks, and intracranial venous thrombosis. In: Donaghy M editor(s). Brain's Diseases of the Nervous System. 11th Edition. Oxford University Press, 2001:775-896.
104. Zhang J, Yang J, Chang X, Zhang C, Zhou H, Liu M. Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials. Neurological Research 2012;34:346-53. [DOI: 10.1179/1743132812Y.0000000022]
105. Sandercock P, Gubitz G, Foley P, Counsell C. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD000029]